Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Breast Cancer

  Free Subscription


Articles published in Anticancer Res

Retrieve available abstracts of 73 articles:
HTML format



Single Articles


    November 2022
  1. MIZRAHI AG, Hamad H, Gugenheim A, Nisman B, et al
    Loss of Heterozygosity of BRCA1/2 as a Predictive Marker for Talazoparib Response.
    Anticancer Res. 2022;42:5257-5263.
    PubMed     Abstract available


  2. TAKAHASHI E, Imai K, Fukuyama M, Terata K, et al
    Changes in Serum Trace Element Concentrations Before and After Surgery in Resectable Breast Cancer.
    Anticancer Res. 2022;42:5323-5334.
    PubMed     Abstract available


  3. XIONG Y, Motomura H, Tamori S, Ozaki A, et al
    High Expression of CD58 and ALDH1A3 Predicts a Poor Prognosis in Basal-like Breast Cancer.
    Anticancer Res. 2022;42:5223-5232.
    PubMed     Abstract available


  4. SCHMITZ V, Bauerschmitz G, Gallwas J, Grundker C, et al
    Suppression of G Protein-coupled Estrogen Receptor 1 (GPER1) Enhances the Anti-invasive Efficacy of Selective ERbeta Agonists.
    Anticancer Res. 2022;42:5187-5194.
    PubMed     Abstract available


  5. SHOJI R, Tsuchie H, Nagasawa H, Hongo M, et al
    Intravascular Administration of Acridine Orange and Zoledronate in a Bone Metastasis Model of Breast Cancer.
    Anticancer Res. 2022;42:5357-5363.
    PubMed     Abstract available


    October 2022
  6. KANAOKA H, Nagahashi M, Atake Y, Hattori A, et al
    Absolute Lymphocyte Count Is an Independent Prognostic Factor for ER-positive HER2-negative Advanced Breast Cancer Patients Treated With CDK4/6 Inhibitors.
    Anticancer Res. 2022;42:4867-4878.
    PubMed     Abstract available


  7. OZAWA H, Higuchi T, Fujimoto Y, Bun A, et al
    Total Lesion Glycolysis Levels as Predictive Indicators in Patients With Metastatic and Recurrent Breast Cancer Undergoing Endocrine Therapy With or Without CDK4/6 Inhibitor.
    Anticancer Res. 2022;42:4813-4824.
    PubMed     Abstract available


  8. MORI T, Furukawa A, Bilal T, Ueda A, et al
    Simultaneous Detection and HER2 Profiling of Circulating Breast Cancer Cells in Clinical Patients Using a Rare Cell Sorter.
    Anticancer Res. 2022;42:4879-4886.
    PubMed     Abstract available


  9. MUGURUMA M, Asaoka M, Teraoka S, Miyahara K, et al
    beta-Tubulin Isoforms Related to Docetaxel Sensitivity in 2D and 3D Cultured TNBC Cell Lines.
    Anticancer Res. 2022;42:4735-4742.
    PubMed     Abstract available


    September 2022
  10. DO J, Chu J, Ahn J, Bae GE, et al
    Assessing Resection Margin Status in Breast-conserving Surgery Specimens: Comparison Among Gross Evaluation, Frozen Section Analysis, and Permanent Section Diagnosis in 725 Patients With Breast Cancer.
    Anticancer Res. 2022;42:4453-4460.
    PubMed     Abstract available


  11. II H, Taniguchi K, Yoshiya T, Nohara Y, et al
    The gamma-Glutamylcyclotransferase Inhibitor Pro-GA Induces an Antiproliferative Effect Through the Generation of Mitochondrial Reactive Oxygen Species.
    Anticancer Res. 2022;42:4311-4317.
    PubMed     Abstract available


  12. SON SW, Heo SH, Oh SS, Lee CH, et al
    Etoposide-induced MicroRNA-205-5p Suppresses Proliferation and Migration by Targeting ERBB4 in MCF-7 Cells.
    Anticancer Res. 2022;42:4265-4272.
    PubMed     Abstract available


    August 2022
  13. TAKADA K, Kashiwagi S, Kouhashi R, Iimori N, et al
    The Effect of Smoking on Endocrine Therapy for Stage IV Hormone Receptor Positive Breast Cancer.
    Anticancer Res. 2022;42:3937-3946.
    PubMed     Abstract available


  14. SHIMAZAKI A, Kubo M, Kurata K, Takao Y, et al
    CCND1 Copy Number Variation in Circulating Tumor DNA from Luminal B Breast Cancer Patients.
    Anticancer Res. 2022;42:4071-4077.
    PubMed     Abstract available


  15. LIAO PA, Chu PY, Tan ZL, Hsu FT, et al
    STAT3 Inactivation and Induction of Apoptosis Associate With Fluoxetine-inhibited Epithelial-mesenchymal Transition and Growth of Triple-negative Breast Cancer In Vivo.
    Anticancer Res. 2022;42:3807-3814.
    PubMed     Abstract available


  16. OGATA N, Toh U, Sudou T, Ogata S, et al
    Efficacy and Safety of Monthly Minodronate Therapy in Postmenopausal Breast Cancer Patients Receiving Aromatase Inhibitors.
    Anticancer Res. 2022;42:4139-4143.
    PubMed     Abstract available


  17. KITANO S, Honda A, Itoi N, Lee T, et al
    Everolimus for Treating Hormone Receptor-positive Metastatic Breast Cancer Previously Treated With Cyclin-dependent Kinase 4/6 Inhibitors.
    Anticancer Res. 2022;42:3913-3919.
    PubMed     Abstract available


  18. WANG YC, Wang ZH, Yen JH, Shen YC, et al
    The Contribution of Interleukin-8 Rs4073 Genotypes to Triple Negative Breast Cancer Risk in Taiwan.
    Anticancer Res. 2022;42:3799-3806.
    PubMed     Abstract available


  19. VANNI G, Pellicciaro M, Materazzo M, Melaiu O, et al
    Neoadjuvant Treatment as a Risk Factor for Variation of Upper Limb Lymph Node Drainage During Axillary Reverse Mapping in Breast Cancer: A Prospective Observational Study.
    Anticancer Res. 2022;42:3879-3888.
    PubMed     Abstract available


  20. TAKIMOTO R, Kamigaki T, Okada S, Ibe H, et al
    Efficacy of Adjuvant Immune-cell Therapy Combined With Systemic Therapy for Solid Tumors.
    Anticancer Res. 2022;42:4179-4187.
    PubMed     Abstract available


    July 2022
  21. NOZAWA K, Takatsuka D, Endo Y, Horisawa N, et al
    Impact of Tumor Progression on Survival During Neoadjuvant Chemotherapy in Breast Cancer: A Cohort Study.
    Anticancer Res. 2022;42:3735-3742.
    PubMed     Abstract available


  22. OZAKI A, Motomura H, Tamori S, Onaga C, et al
    High Expression of p62 and ALDH1A3 Is Associated With Poor Prognosis in Luminal B Breast Cancer.
    Anticancer Res. 2022;42:3299-3312.
    PubMed     Abstract available


  23. SAITO Y, Takekuma Y, Takeshita T, Noguchi T, et al
    Risk Factor Analysis for the Occurrence of Severe Adverse Effects in Eribulin Treatment.
    Anticancer Res. 2022;42:3693-3700.
    PubMed     Abstract available


  24. SAITO Y, Takekuma Y, Takeshita T, Sugawara M, et al
    Influence of Dose Reduction of Prophylactic Dexamethasone on Chemotherapy-induced Nausea and Anorexia in Patients Under 55 Years Old Treated With Anthracycline-containing Regimens.
    Anticancer Res. 2022;42:3753-3758.
    PubMed     Abstract available


  25. SAEED MEM, Drif AI, Efferth T
    Biomarker Profiling Revealed Carcinoembryonic Antigen as a Target of Artesunate in a Ductal Breast Cancer Patient.
    Anticancer Res. 2022;42:3483-3494.
    PubMed     Abstract available


  26. CHOI HY, Lee HJ, Moon KM, Moon DK, et al
    Up-regulation of CPNE1 Appears to Enhance Cancer Progression in HER2-positive and Luminal A Breast Cancer Cells.
    Anticancer Res. 2022;42:3445-3452.
    PubMed     Abstract available


  27. NIGUMA K, Mamishin K, Naito Y, Nomura S, et al
    Impact of Older Age and Medico-social Factors on the Decision to Offer Adjuvant Chemotherapy to Patients With Breast Cancer.
    Anticancer Res. 2022;42:3743-3751.
    PubMed     Abstract available


    June 2022
  28. RADES D, Narvaez CA, Dziggel L, Splettstosser L, et al
    Improvement of Sleep Disorders During a Course of Radiotherapy for Breast Cancer - Final Results of the Prospective Interventional RADIO-SLEEP Trial.
    Anticancer Res. 2022;42:3085-3089.
    PubMed     Abstract available


  29. ROSENKAIMER S, Sieburg T, Winter L, Mavratzas A, et al
    Adverse Cardiovascular Effects of Anti-tumor Therapies in Patients With Breast Cancer: A Single-center Cross-sectional Analysis.
    Anticancer Res. 2022;42:3075-3084.
    PubMed     Abstract available


  30. YEHIA ZA, Yoon J, Sayan M, Kumar S, et al
    Does the Use of BioZorb((R)) Result in Smaller Breast Seroma Volume?
    Anticancer Res. 2022;42:2961-2965.
    PubMed     Abstract available


    May 2022
  31. CHUNG Y, Kim S, Kim HS, DO SI, et al
    High Receptor-interacting Serine/Threonine-protein Kinase 3 (RIP3) Expression Serves as an Independent Poor Prognostic Factor for Triple-negative Breast Carcinoma.
    Anticancer Res. 2022;42:2753-2761.
    PubMed     Abstract available


  32. HAN M, Yamaguchi S, Onishi M, Fujii T, et al
    The MDM2 and CDKN2A Copy-number-variation Influence the TP53-signature-score in Wild-type TP53 Luminal Type Breast Cancer.
    Anticancer Res. 2022;42:2277-2288.
    PubMed     Abstract available


  33. TAKEMURA M, Ikemura K, Yoshinami T, Toyozumi Y, et al
    Proton Pump Inhibitors Ameliorate Capecitabine-induced Hand-Foot Syndrome in Patients With Breast Cancer: A Retrospective Study.
    Anticancer Res. 2022;42:2591-2598.
    PubMed     Abstract available


  34. TUOHINEN SS, Skytta T, Huhtala H, Virtanen V, et al
    Dynamic Integrated Backscatter Detects Radiotherapy-induced Cardiac Changes Better than Strain Analysis - A Prospective Three-year Study.
    Anticancer Res. 2022;42:2507-2517.
    PubMed     Abstract available


  35. NISHIMURA M, Imaoka T, Daino K, Nishimura Y, et al
    Copenhagen Rats Display Dominantly Inherited Yet Non-uniform Resistance to Spontaneous, Radiation-induced, and Chemically-induced Mammary Carcinogenesis.
    Anticancer Res. 2022;42:2415-2423.
    PubMed     Abstract available


    April 2022
  36. TANAKA M, Yamashita SI, Yoshinaga Y, Enomoto Y, et al
    Combination of DYRK2 and TERT Expression Is a Powerful Predictive Marker for Early-stage Breast Cancer Recurrence.
    Anticancer Res. 2022;42:2079-2085.
    PubMed     Abstract available


  37. PARK HL, Yang B, Shin JE, Kim JY, et al
    Additional Excision Biopsy in Patients With Atypical Ductal Hyperplasia at Ultrasound-guided Vacuum-assisted Breast Biopsy.
    Anticancer Res. 2022;42:2159-2165.
    PubMed     Abstract available


    March 2022
  38. KASHIWAGI S, Asano Y, Takada K, Goto W, et al
    Outcome Prediction After Neoadjuvant Chemotherapy (NAC) for Breast Cancer, Using Tumor-infiltrating Lymphocytes Within Fibrotic Foci of Tumor Stroma (FF-TILs).
    Anticancer Res. 2022;42:1421-1431.
    PubMed     Abstract available


  39. OKAMOTO A, Funakoshi Y, Oe M, Takai R, et al
    Identification of Breast Cancer Stem Cells Using a Newly Developed Long-acting Fluorescence Probe, C5S-A, Targeting ALDH1A1.
    Anticancer Res. 2022;42:1199-1205.
    PubMed     Abstract available


  40. DANTAS FT, Felix-Silva PH, Angotti-Carrara HH, Dos-Reis FJC, et al
    A New Method for Obtaining Tumor Interstitial Fluid Applied to Cytokine Analysis of Breast Carcinoma Samples.
    Anticancer Res. 2022;42:1327-1332.
    PubMed     Abstract available


    February 2022
  41. SEKI H, Sakurai T, Sakurada A, Kinoshita T, et al
    Subsequent-abemaciclib Treatment After Disease Progression on Palbociclib in Patients With ER-positive HER2-negative Metastatic Breast Cancer.
    Anticancer Res. 2022;42:1099-1106.
    PubMed     Abstract available


  42. ALEXOPOULOS A, Karanikiotis C, Ardavanis A, Boukovinas I, et al
    Safety and Efficacy of RAD001 (Everolimus) Administered Upon Relapse During or After Adjuvant Treatment in Post-menopausal Women With Hormone Receptor Positive, HER2/neu Negative Locally Advanced or Metastatic Breast Cancer (CRAD001JGR08 "MELPOMENI" s
    Anticancer Res. 2022;42:1031-1041.
    PubMed     Abstract available


  43. WAZIR U, Patani N, Heeney J, Mokbel K, et al
    Pre-pectoral Immediate Breast Reconstruction Following Conservative Mastectomy Using Acellular Dermal Matrix and Semi-smooth Implants.
    Anticancer Res. 2022;42:1013-1018.
    PubMed     Abstract available


  44. GOTO W, Kashiwagi S, Takada K, Asano Y, et al
    Utility of Follow-up With Absolute Lymphocyte Count in Patients Undergoing Eribulin Treatment for Early Detection of Progressive Advanced or Metastatic Breast Cancer.
    Anticancer Res. 2022;42:939-946.
    PubMed     Abstract available


  45. NIEDER C, Ressheim J, Haukland EC, Mannsaker B, et al
    Implementation of Locoregional Adjuvant Radiotherapy for Breast Cancer in a Rural Healthcare Region: Toxicity Outcomes in the Initial Cohort.
    Anticancer Res. 2022;42:923-928.
    PubMed     Abstract available


  46. COMSA S, Ceausu AR, Popescu R, Cimpean AM, et al
    Patterns of Tumor Vasculogenesis on a Chick Embryo Chorioallantoic Membrane In Vivo Model of Breast Cancer.
    Anticancer Res. 2022;42:877-883.
    PubMed     Abstract available


  47. HO CY, Hu DW, Chen BR, Yang CC, et al
    Snail Mucus Enhances Chemosensitivity of Triple-negative Breast Cancer Via Activation of the Fas Pathway.
    Anticancer Res. 2022;42:845-855.
    PubMed     Abstract available


  48. GOHNO T, Hanamura T, Kurosumi M, Takei H, et al
    One DNA Methylation Regulates CHIP Gene Expression of Human Breast Cancer and Predicts Recurrence.
    Anticancer Res. 2022;42:759-766.
    PubMed     Abstract available


  49. SONG C, Kendi AT, Lowe VJ, Lee S, et al
    The A20/TNFAIP3-CDC20-CASP1 Axis Promotes Inflammation-mediated Metastatic Disease in Triple-negative Breast Cancer.
    Anticancer Res. 2022;42:681-695.
    PubMed     Abstract available


  50. MOKBEL K, Mokbel K
    The Role of Community Pharmacists in Addressing Medication-related Issues for Breast Cancer Patients Receiving Adjuvant Endocrine Therapy.
    Anticancer Res. 2022;42:661-666.
    PubMed     Abstract available


    January 2022
  51. MAZAKI AI, Yamauchi K, Orita S, Inage K, et al
    Nerve Growth Factor in Breast Cancer Cells Promotes Axonal Growth and Expression of Calcitonin Gene-related Peptide in a Rat Model of Spinal Metastasis.
    Anticancer Res. 2022;42:581-587.
    PubMed     Abstract available


  52. HENRIQUES PALMA GB, Kaur M
    Cholesterol Depletion Modulates Drug Resistance Pathways to Sensitize Resistant Breast Cancer Cells to Tamoxifen.
    Anticancer Res. 2022;42:565-579.
    PubMed     Abstract available


  53. HOSOYA K, Nosaka K, Sakabe T, Wakahara M, et al
    Clinical Significance of Serglycin Expression in Human Breast Cancer Patients.
    Anticancer Res. 2022;42:279-285.
    PubMed     Abstract available


  54. MEIROVITZ A, Nisman B, Allweis TM, Carmon E, et al
    Thyroid Hormones and Morphological Features of Primary Breast Cancer.
    Anticancer Res. 2022;42:253-261.
    PubMed     Abstract available


  55. ASANO Y, Kashiwagi S, Takada K, Ishihara S, et al
    Clinical Significance of Expression of Immunoadjuvant Molecules (LAG-3, TIM-3, OX-40) in Neoadjuvant Chemotherapy for Breast Cancer.
    Anticancer Res. 2022;42:125-136.
    PubMed     Abstract available


  56. SAYAN M, Vergalasova I, Jan I, Kumar S, et al
    Toxicities and Locoregional Control After External Beam Chest Wall and/or Regional Lymph Node Re-irradiation for Recurrent Breast Cancer.
    Anticancer Res. 2022;42:93-96.
    PubMed     Abstract available


  57. SAYAN M, Yehia ZA, Jan I, Gupta A, et al
    Adaptive Lumpectomy Boost Planning Can Reduce Normal Tissue Exposure in Patients Receiving Hypofractionated Whole Breast Irradiation.
    Anticancer Res. 2022;42:53-57.
    PubMed     Abstract available


  58. TAKADA K, Kashiwagi S, Asano Y, Goto W, et al
    The Effect of Smoking on Progression from Ductal Carcinoma In Situ to Invasive Ductal Breast Carcinoma: A Retrospective Study.
    Anticancer Res. 2022;42:311-320.
    PubMed     Abstract available


    December 2021
  59. MAMISHIN K, Naito Y, Nomura S, Ogawa G, et al
    Comparison of Treatment Completion Rate Between Conventional and Dose-dense Doxorubicin and Cyclophosphamide (AC) Followed by a Taxane in Patients With Breast Cancer: A Propensity Score-matched Analysis.
    Anticancer Res. 2021;41:6217-6224.
    PubMed     Abstract available


  60. HONG SE, Jin HO, Kim SM, Jang SK, et al
    miR-3188 Enhances Sensitivity of Breast Cancer Cells to Ionizing Radiation by Down-regulating Rictor.
    Anticancer Res. 2021;41:6169-6176.
    PubMed     Abstract available


  61. MOTOMURA H, Tamori S, Yatani MA, Namiki A, et al
    GLO 1 and PKClambda Regulate ALDH1-positive Breast Cancer Stem Cell Survival.
    Anticancer Res. 2021;41:5959-5971.
    PubMed     Abstract available


  62. ACUNA UM, Ezzone N, Rakotondraibe LH, Carcache DE Blanco EJ, et al
    Activity in MCF-7 Estrogen-sensitive Breast Cancer Cells of Capsicodendrin from Cinnamosma fragrans.
    Anticancer Res. 2021;41:5935-5944.
    PubMed     Abstract available


  63. KANGA KJW, Mendonca P, Soliman KFA, Ferguson DT, et al
    Effect of Diallyl Trisulfide on TNF-alpha-induced CCL2/MCP-1 Release in Genetically Different Triple-negative Breast Cancer Cells.
    Anticancer Res. 2021;41:5919-5933.
    PubMed     Abstract available


  64. NOMURA T, Kurebayashi J, Moriya T, Saito W, et al
    A Case of Rare Matrix-producing Triple-negative Breast Carcinoma for Which Drug Response in a Patient-derived Orthotopic Xenograft Mouse Model Was Correlated With Patient Response.
    Anticancer Res. 2021;41:6191-6197.
    PubMed     Abstract available


  65. COLLERY P, Veena V, Desmaele D, Harikrishnan A, et al
    Effects of Rhenium(I)-diselenoether and of its Diselenide Ligand on the Production of Cathepsins B and S by MDA-MB231 Breast Malignant Cells.
    Anticancer Res. 2021;41:5997-6001.
    PubMed     Abstract available


    November 2021
  66. TOKISAWA H, Aruga T, Honda Y, Ishiba T, et al
    Safety and Effectiveness of Areola-sparing Mastectomy for Breast Cancer With Intraductal Lesions.
    Anticancer Res. 2021;41:5723-5728.
    PubMed     Abstract available


  67. PIANKA J, Gruba N, Kitowska K, Mieczkowski K, et al
    Simplified Theta-defensin [Ser(3,7,12,16)] RTD-2 Analog Is Involved in Proteasomal Degradation Pathway in Breast Cancer.
    Anticancer Res. 2021;41:5415-5423.
    PubMed     Abstract available


  68. VANNI G, Caiazza G, Materazzo M, Storti G, et al
    Erector Spinae Plane Block Versus Serratus Plane Block in Breast Conserving Surgery: Alpha Randomized Controlled Trial.
    Anticancer Res. 2021;41:5667-5676.
    PubMed     Abstract available


  69. VANNI G, Pellicciaro M, Sadri A, Tacconi F, et al
    Pre-pectoral Breast Reconstruction Does Not Affect Early Immunological Response: A BIAL 2.20 Study Subanalysis.
    Anticancer Res. 2021;41:5657-5665.
    PubMed     Abstract available


    October 2021
  70. FRIEDRICH RE, Madani E
    Consolidation of Tumorous Mandibular Ramus Defect During Denosumab Treatment for Rapidly Progressive Metastatic Breast Cancer.
    Anticancer Res. 2021;41:5081-5087.
    PubMed     Abstract available


  71. VAHAAHO N, Hakamies-Blomqvist L, Blomqvist C, Kellokumpu-Lehtinen PL, et al
    Sense of Coherence as Predictor of Quality of Life in Early Breast Cancer Patients.
    Anticancer Res. 2021;41:5045-5052.
    PubMed     Abstract available


  72. TAKASHIMA T, Nishimura S, Kawajiri H, Mizuyama Y, et al
    An Exploratory Phase II Study of Eribulin Re-challenge After Short Term Therapy of 5-Fluorouracil for HER2 Negative, Advanced or Recurrent Breast Cancer.
    Anticancer Res. 2021;41:5007-5014.
    PubMed     Abstract available


  73. WU NF, Yamamoto J, Aoki Y, Masaki N, et al
    The Combination of Cisplatinum and Doxorubicin Regressed Primary Osteosarcoma of the Breast in a PDOX Mouse Model.
    Anticancer Res. 2021;41:4715-4718.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: